Kaposi Sarcoma Market Outlook, Top Key Players, Industry Growth Analysis and Forecast to 2022

Kaposi Sarcoma Market Outlook, Top Key Players, Industry
Growth Analysis and Forecast to 2022
Kaposi Sarcoma Market report on is foretold to provide a robust
support for industry players to lay a solid foundation for their
business growth. It includes a comprehensive evaluation of the
market’s growth status and market risk. Furthermore, it provides
detail industry analysis - porter’s, market variables, trends & key
opportunities.
Kaposi Sarcoma is a tumor caused by infection with human herpes virus 8. It is also known as Kaposi
sarcoma-associated herpes virus or KS agent. It becomes widely known as one of the AIDS-defining
illnesses. It is viral infection. There is a widespread lack of awareness of this even among persons at
risk for HHV-8 infection. Kaposi sarcoma (KS) is a systemic disease with cutaneous lesions with or
without internal involvement. The Kaposi sarcoma (KS) is considered to be an AIDS-defining disease;
indicating that patients with KS go on to develop AIDS. The incidence of Kaposi sarcoma was
reportedly high in homosexual men with HIV. Kaposi Sarcoma is different from the other cancers in
that lesions may be in more than one place in the body at the same time. These affected areas are
called lesions. The skin lesions of KS most often appear on the legs or face and may cause it to swell
painfully.

Browse Full Research Report @
https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market
KS can cause serious problems or even become life treating when the lesions are in the lungs, liver,
or in digestive tract. The means that the when KS occurs in someone is infected with HIV.
Chemotherapy, immunotherapy, and antiretroviral therapy (HAART) are the key treatment methods
for Kaposi sarcoma. The HAART therapy emerged as the leading segment owing to the high
incidence of AIDS-related Kaposi sarcoma globally. HAART therapy includes the combination of
reverse transcriptase (RT) inhibitors, fusion inhibitors, and protease inhibitors. Chemotherapy is
likely to grow at the fastest pace during the forecast period due to the high cost of the treatment
and the increasing adoption by immunocompentent patients.
The leading chemotherapy drugs include paclitaxel, liposomal doxorubicin and daunorubicin,
bleomicin and vincristine. Immunotherapy consists of interferon alfa; which is the first biological
drug approved by the FDA to the treatment of Kaposi sarcoma. Patients with good immune
functions show effectiveness. However, immune compromised patients rarely respond to this
therapy. The therapy accounted for the least share in the global market. Kaposi Sarcoma Market by
Type of Treatment is segmented into Chemotherapy, Liposomal Anthracyclines, Alkaloids,
Immunotherapy, HAART. Kaposi Sarcoma Market by Distribution Channel is segmented into
Hospitals, Cancer Research Institutes, Multispecialty Clinics, Ambulatory Surgical Centers.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market/request-sample
Kaposi Sarcoma Market by Geographical Region is segmented into North America, Latin America,
Europe, Asia-Pacific, and the Middle East and Africa. North America contributed to the major share
in the Kaposi sarcoma market in 2015. Due to the presence of key market players and the increasing
cost of drugs; the growth of the market is also driven by the easy availability of drugs and a high
diagnosis rate of the malignancy. The high cost of the therapy is a deterrent to patients in
developing regions such as Asia Pacific and the Middle East and Africa and this limits its adoption. A
limited number of approved biologics is also a prominent factor restraining the growth of the
immunotherapy segment. The Middle East and Africa are expected to expand at the highest CAGR
during the forecast period owing to the high incidence and prevalence of KS in Eastern Africa. The
trend is consistent with the geographic variations of the HIV/AIDS epidemic. The key players include
Aphios Corporation, AstraZeneca Plc, Biogenomics Limited, and CytRx Corporation. Eli Lilly and Co.,

Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough
Corporation (Merck & Co., Inc.).
Market Segment:
This report focuses on top manufacturers in global market, with production, price, revenue and
market share for each manufacturer, covering
• Merck
• Johnson & Johnson
• GlaxoSmithKline
• Bristol-Myers Squibb
• Eli Lilly and Pfizer
By types, the market can be split into
• HAART
• Chemotherapy
• Immunotherapy
By Application, the market can be split into
• Hospitals
• Clinics
• Other
By Regions, this report covers (we can add the regions/countries as you want)
• North America
• China
• Europe
• Southeast Asia
• Japan
• India
See More Reports of this Category by Million Insights @
https://www.millioninsights.com/industry/healthcare

Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction.
Our representatives strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: ryan@millioninsights.com
Global Headquarters
Million Insights
Felton Office Plaza 6265 Highway 9
Felton, California 95018, United States
Phone: 1-408-610-2300
Email: sales@millioninsights.com
Asia Pacific
Million Insights
Office No. 302, 3rd Floor, Manikchand
Galleria, Model Colony, Shivaji Nagar,
Pune, MH, 411016 India
Phone: 91-20-65300184
Email: sales@millioninsights.com
Visit Our Blog: www.millioninsights.blogspot.com